EP3843745A1 - Procédés et compositions pour le traitement de neuroblastome dans un corps de mammifère juvénile - Google Patents

Procédés et compositions pour le traitement de neuroblastome dans un corps de mammifère juvénile

Info

Publication number
EP3843745A1
EP3843745A1 EP19855576.5A EP19855576A EP3843745A1 EP 3843745 A1 EP3843745 A1 EP 3843745A1 EP 19855576 A EP19855576 A EP 19855576A EP 3843745 A1 EP3843745 A1 EP 3843745A1
Authority
EP
European Patent Office
Prior art keywords
taurolidine
administered
neuroblastoma
nanoparticle
site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19855576.5A
Other languages
German (de)
English (en)
Other versions
EP3843745A4 (fr
Inventor
Bruce Reidenberg
Robert Diluccio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cormedix Inc
Original Assignee
Cormedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cormedix Inc filed Critical Cormedix Inc
Publication of EP3843745A1 publication Critical patent/EP3843745A1/fr
Publication of EP3843745A4 publication Critical patent/EP3843745A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention relates to therapeutic methods and compositions in general, and more particularly to therapeutic methods and compositions for the treatment of neuroblastoma in a juvenile mammalian body.
  • NB Neuroblastoma
  • neuroblastoma extracranial solid cancer in childhood, and the most common cancer in infancy, with an incidence of about six hundred fifty cases per year in the U.S., and a hundred cases per year in the UK. Nearly half of neuroblastoma cases occur in children younger than two years. It is a neuroendocrine tumor, arising from any neural crest element of the sympathetic nervous system (SNS) . Neuroblastoma most frequently originates in one of the adrenal glands, but can also develop in nerve tissues in the neck, chest, abdomen, or pelvis. Note that while neuroblastoma arises from nerve tissues, it is not a tumor of the central nervous system ( CNS ) .
  • CNS central nervous system
  • Neuroblastoma is one of the few human
  • Neuroblastoma is a disease exhibiting extreme heterogeneity, and is stratified into three risk categories: low-risk, intermediate-risk, and high- risk. Low-risk neuroblastoma is most common in infants and good outcomes are common with observation only or surgery, whereas high-risk neuroblastoma is difficult to treat successfully even with the most intensive multi-modal therapies available.
  • therapy e.g., intensive chemotherapy, surgery, radiation therapy, stem cell transplant,
  • differentiation agent isotrentinoin (also called 13- cis-retinoic acid) , and frequently immunotherapy with anti-GD2 immunotherapy with anti-GD2 monoclonal antibody therapy.
  • High-risk neuroblastoma is generally treated with intensive chemotherapy, surgery, radiation therapy, bone marrow/hematopoietic stem cell transplantation, biological-based therapy with 13-cis-retinoic acid (isotretinoin or Accutane) and antibody therapy
  • cytokines GM-CSF and IL-2. cytokines
  • Chemotherapy agents used in combination have been found to be effective against neuroblastoma. Agents commonly used in induction and for stem cell
  • transplant conditioning are platinum compounds
  • topoisomerase I inhibitors topotecan and irinotecan in induction which have been found to be effective against recurrent disease.
  • taurolidine is used to treat neuroblastoma in juvenile mammalian bodies.
  • the taurolidine is given with a dosage range of from 5 mg/kg to 280 mg/kg, and preferably with a dosage range of between 5 mg/kg and 60 mg/kg.
  • This dosage is administered from once daily through weekly for an effective period of time based on individual patient response.
  • the taurolidine is delivered systemically, preferably either intravenously (more preferred) or intramuscularly .
  • the taurolidine is delivered systemically in a "shielded form" so that hydrolysis of the taurolidine is delayed until the taurolidine reaches the site of the
  • the taurolidine may be delivered as a single agent or in combination with one or more oncolytic agents and/or radiotherapy.
  • a method for treating neuroblastoma in juvenile mammals comprising administering taurolidine to the juvenile mammal.
  • the taurolidine is administered with a dosage range of from 5 mg/kg to 280 mg/kg, for an effective period of time, based on individual patient response.
  • the taurolidine is administered with a dosage range of from 5 mg/kg and 60 mg/kg.
  • the dosage is administered from once daily through weekly.
  • the taurolidine is administered systemically .
  • the taurolidine is administered intravenously.
  • the taurolidine is administered intramuscularly.
  • the taurolidine is included in a nanoparticle, and the nanoparticle is configured to delay hydrolysis of the taurolidine until the nanoparticle reaches the site of a tumor.
  • the taurolidine is included in a nanoparticle, the nanoparticle comprises a taurolidine core and an exterior coating, and the exterior coating is configured to prevent exposure of the taurolidine prior to arrival of the nanoparticle at the site of the tumor.
  • the taurolidine is included in a nanoparticle, the nanoparticle comprises a taurolidine core and an exterior coating, and the exterior coating comprises an absorbable polymer or lipid which breaks down as the nanoparticle travels from the site of insertion to the site of the tumor.
  • the taurolidine is delivered using a polymer system which is configured to delay hydrolysis of the taurolidine.
  • the taurolidine is delivered using a polymer system, with the taurolidine being “pegylated” using polyethylene glycols (PEGs) to delay premature of hydrolysis of taurolidine.
  • PEGs polyethylene glycols
  • the taurolidine is administered to humans. In one form of the invention, the taurolidine is administered to at least one from the group consisting of infants, children and adolescents.
  • the taurolidine is administered as a single agent.
  • the taurolidine is administered in combination with at least one
  • the taurolidine is administered in combination with at least one
  • the at least one oncolytic agent is selected from the group consisting of platinum compounds (cisplatin, carboplatin) , alkylating agents (cyclophosphamide, ifosfamide, melphalan,
  • the taurolidine is administered in combination with radiotherapy.
  • Fig. 1 is a graph showing that leukemia cell lines appear more sensitive to the effects of
  • taurolidine compared to healthy lymphocytes in vitro ( not in vivo ) ;
  • Fig. 2 is a graph showing that neuroblastoma cell lines are more sensitive to a decrease in viability due to taurolidine when compared to healthy
  • Figs. 3-6 are graphs or photographs showing that taurolidine given to CB57 SCID mice with measurable tumors from a neuroblastoma cell line implanted subcutaneously in the CB57 SCID mice has efficacy in
  • Figs. 7 and 8 are graphs showing that
  • Taurolidine is a well known antimicrobial with a published mechanism of action and antimicrobial spectrum. Taurolidine is unstable in circulation and therefore has not been successfully developed for systemic infections. Taurolidine has demonstrated efficacy in local application for peritonitis and for prevention of infection when infused as a catheter- lock solution.
  • Taurolidine has recently been investigated for oncolytic activity and found to have inhibitory effect on cell lines in culture, in combination with standard chemotherapy or alone. Despite claims that in vitro inhibitory concentrations are clinically achievable, the only published human pharmacokinetic study showed NO measurable concentration of taurolidine in healthy volunteers when 5 grams of taurolidine were given intravenously by 20 minute infusion. This is believed to be due to the rapid hydrolysis of taurolidine when administered systemically in a mammalian body.
  • neuroblastoma cell lines are more sensitive to a decrease in viability due to taurolidine when compared to healthy
  • taurolidine given to CB57 SCID mice with measurable tumors from a neuroblastoma cell line implanted subcutaneously in the CB57 SCID mice showed efficacy in IMR5 tumors and measurable efficacy in SK- N-AS tumors in vivo (not in vitro) . See Figs. 3-6.
  • taurolidine may be used to treat neuroblastoma in a juvenile mammalian body .
  • the taurolidine is given with a dosage range of from 5 mg/kg to 280 mg/kg, and preferably with a dosage range of between 5 mg/kg and 60 mg/kg.
  • Effective dosage was computed by computing the human equivalent dosage from the effective mouse dose, using the following formula:
  • This dosage is administered from once daily through weekly for an effective period of time based on individual patient response.
  • the taurolidine is delivered systemically, preferably either intravenously (more preferred) or intramuscularly.
  • intravenously more preferred
  • intramuscularly preferably either intravenously (more preferred) or intramuscularly.
  • the taurolidine is delivered systemically in a "shielded form" so that hydrolysis of the
  • taurolidine is delayed until the taurolidine reaches the site of the neuroblastoma, whereupon hydrolysis of the taurolidine occurs.
  • the taurolidine is delivered in the form of a nanoparticle, where the nanoparticle comprises a taurolidine core and an exterior coating which is configured to prevent premature exposure of the taurolidine prior to the arrival of the nanoparticle to the tumor site.
  • the exterior coating breaks down as the nanoparticle travels from the site of insertion to the site of the tumor so as to release the taurolidine for hydrolysis at the site of the tumor.
  • the coating comprises an absorbable polymer or lipid which breaks down as the nanoparticle travels from the site of insertion to the site of the tumor.
  • the coating can be created from combinations of copolymers and multimers derived from polymers structured from 1-lactide, glycolide, e- caprolactone, p-dioxanone, and trimethylene carbonate.
  • the coating may also be associated with glycols such as polyethylene glycols (PEGs), which can either be linear or multi-arm structures.
  • PEGs polyethylene glycols
  • the nanoparticle may comprise an excipient (e.g., a buffer for providing enhanced hydrolytic stability of the taurolidine within the nanoparticle) .
  • an excipient e.g., a buffer for providing enhanced hydrolytic stability of the taurolidine within the nanoparticle
  • the nanoparticle can further comprise a coating, wherein the coating is configured to target the nanoparticle to the site of a neuroblastoma so as to improve the efficacy of the taurolidine for treatment of the neuroblastoma.
  • the coating comprises binding molecules which are configured to target delivery of the nanoparticle to specific tissue.
  • the coating for the nanoparticle comprises a monoclonal antibody against N-type calcium channels (e.g., an anti-N-type calcium channel exofacial Fab fragment) for causing the nanoparticle to bind to neural tissue (e.g., to a neuroblastoma tumor) .
  • the taurolidine may be delivered using a polymer system which is configured to delay hydrolysis of the taurolidine and/or optimize the release properties of the
  • taurolidine may be “pegylated” using polyethylene glycols (PEGs) to delay premature of hydrolysis of taurolidine and/or optimize the release properties of the taurolidine.
  • PEGs polyethylene glycols
  • the taurolidine may be delivered as a single agent or in combination with one or more oncolytic agents and/or radiotherapy.
  • oncolytic agents that can be combined with taurolidine for delivery to a juvenile mammal for treating
  • neuroblastoma are platinum compounds (cisplatin, carboplatin) , alkylating agents (cyclophosphamide, ifosfamide, melphalan, topoisomerase II inhibitor), vinca alkaloids (vincristine), and topoisomerase I inhibitors (topotecan and irinotecan) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Le neuroblastome est une tumeur affectant principalement les enfants. Le niveau actuel des soins n'est pas curatif sauf dans le cas rare d'une lésion résécable chirurgicalement, même si des taux élevés de survie ont été enregistrés pour le neuroblastome à faible risque et le neuroblastome à risque modéré. La taurolidine a été développée en tant qu'agent anti-infectueux, mais on a constaté qu'elle présente une activité oncolytique surprenante dans des cultures cellulaires et maintenant dans un modèle de cancer de rongeurs. La présente invention concerne l'utilisation de la taurolidine pour le traitement de neuroblastome chez des mammifères juveniles.
EP19855576.5A 2018-08-28 2019-08-28 Procédés et compositions pour le traitement de neuroblastome dans un corps de mammifère juvénile Pending EP3843745A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862723592P 2018-08-28 2018-08-28
PCT/US2019/048579 WO2020047103A1 (fr) 2018-08-28 2019-08-28 Procédés et compositions pour le traitement de neuroblastome dans un corps de mammifère juvénile

Publications (2)

Publication Number Publication Date
EP3843745A1 true EP3843745A1 (fr) 2021-07-07
EP3843745A4 EP3843745A4 (fr) 2022-06-15

Family

ID=69645361

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19855576.5A Pending EP3843745A4 (fr) 2018-08-28 2019-08-28 Procédés et compositions pour le traitement de neuroblastome dans un corps de mammifère juvénile

Country Status (7)

Country Link
EP (1) EP3843745A4 (fr)
JP (1) JP7530351B2 (fr)
KR (1) KR20210050543A (fr)
CN (1) CN113164491A (fr)
AU (1) AU2019330831A1 (fr)
CA (1) CA3111015A1 (fr)
WO (1) WO2020047103A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
AU784539B2 (en) * 1999-12-06 2006-04-27 Geistlich Pharma Ag Methods of treating tumors
EP1442753B1 (fr) * 2003-02-03 2007-02-21 Polaschegg, Hans-Dietrich, Dr.techn. Composition pour la prévention des infections par prothèses endovasculaires
JP2007537200A (ja) * 2004-05-14 2007-12-20 ハンス−ディートリヒ・ポラシェグ タウロリジン製剤及び投与：細菌マイクロフィルム形成に対する治療処置及び抗菌保護
HUE034822T2 (en) * 2012-06-18 2018-03-28 Geistlich Pharma Ag Oxatiazine derivatives as antibacterial and anticancer agents
US20180185378A1 (en) * 2017-01-05 2018-07-05 Cormedix Inc. Antimicrobial delivery system for the prevention and treatment of infections in the colon
CN108778339A (zh) * 2016-01-11 2018-11-09 科医公司 用于治疗神经母细胞瘤及其他癌症的治疗性纳米颗粒
CN106974901A (zh) * 2016-01-18 2017-07-25 贵州益佰制药股份有限公司 洛铂在制备治疗神经母细胞瘤药物中的应用

Also Published As

Publication number Publication date
WO2020047103A1 (fr) 2020-03-05
EP3843745A4 (fr) 2022-06-15
CN113164491A (zh) 2021-07-23
CA3111015A1 (fr) 2020-03-05
AU2019330831A1 (en) 2021-04-29
JP7530351B2 (ja) 2024-08-07
JP2021535173A (ja) 2021-12-16
KR20210050543A (ko) 2021-05-07

Similar Documents

Publication Publication Date Title
Yin et al. Transglutaminase 2 inhibition reverses mesenchymal transdifferentiation of glioma stem cells by regulating C/EBPβ signaling
Moding et al. Strategies for optimizing the response of cancer and normal tissues to radiation
US20230390300A1 (en) Neuroblastoma treatment with taurolidine hydrolysis products
Van Meir et al. Exciting new advances in neuro‐oncology: the avenue to a cure for malignant glioma
US20220323450A1 (en) Methods and compositions for treating neuroblastoma in a juvenile mammalian body
Quan et al. Brain metastases in small cell lung cancer
Nesvick et al. Case-based review: atypical teratoid/rhabdoid tumor
CN108135901A (zh) 胆管癌的治疗
Wu et al. A novel peptide to treat oral mucositis blocks endothelial and epithelial cell apoptosis
Kerbel Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs
Suntharalingam et al. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT)
AU2019330954A1 (en) Neuroblastoma treatment with taurolidine hydrolysis products
Den Otter et al. Role of marker lesion when applying intravesical instillations of IL-2 for non-muscle-invasive bladder cancer comparison of the therapeutic effects in two pilot studies
WO2020047103A1 (fr) Procédés et compositions pour le traitement de neuroblastome dans un corps de mammifère juvénile
JP2023549698A (ja) がんの治療のためのナノ粒子の組成物
Sesink The molecular and cellular consequences of AsiDNA™ combined with radiotherapy on healthy tissue
US12053478B2 (en) Taurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies
Buie et al. Current Treatment Options for the Management of Glioblastoma Multiforme.
Ostanin Controlled Eosinophilic Syndrome Against Cancer. Scientific Discovery and Practical Aspects of Immunotherapy
Woloschak 2019 ASTRO RADIATION AND CANCER BIOLOGY STUDY GUIDE
Reda DEVELOPMENT OF NOVEL NANOPARTICLE BASED PLK1, EGFR, AND PD-L1 TARGETED THERAPIES FOR LUNG CANCER
CN115137748A (zh) 介孔二氧化硅-氧化铈-miR129复合材料及其制备方法和应用
CA3111100A1 (fr) Traitement a la taurolidine pour des tumeurs exprimant des genes myc dans des corps de mammifere
Chan Understanding cancer therapies
Nesvick et al. Neuro-Oncology Practice

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20210326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220517

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 49/00 20060101ALI20220511BHEP

Ipc: A61K 31/00 20060101ALI20220511BHEP

Ipc: A61K 31/198 20060101ALI20220511BHEP

Ipc: A61P 35/00 20060101ALI20220511BHEP

Ipc: A61K 47/60 20170101ALI20220511BHEP

Ipc: A61K 47/10 20170101ALI20220511BHEP

Ipc: A61K 35/00 20060101ALI20220511BHEP

Ipc: A61K 33/243 20190101ALI20220511BHEP

Ipc: A61K 31/675 20060101ALI20220511BHEP

Ipc: A61K 31/555 20060101ALI20220511BHEP

Ipc: A61K 31/475 20060101ALI20220511BHEP

Ipc: A61K 31/4745 20060101ALI20220511BHEP

Ipc: A61K 9/14 20060101ALI20220511BHEP

Ipc: A61K 31/549 20060101ALI20220511BHEP

Ipc: A61K 31/541 20060101ALI20220511BHEP

Ipc: A61K 31/54 20060101AFI20220511BHEP